Neuromuscular HOMEepAGE

neuromuscular.wustl.edu

/

C. Anti-GM1 Antibodies

Immune/Antibody

View full entry on WUSTL Neuromuscular

antibody/motpn2.htm#C. Anti-GM1 Antibodies

Overview

From WUSTL Neuromuscular

Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1'Ceramide 3 | Neu5Acα2 GM1 ganglioside Co-GM1IgM anti-GM1 antibodiesMMND-LMN syndromesacute motor neuropathies without evidence of demyelinationNP-9IgG binding to GM1 ganglioside A major issue regarding clinical testing for anti-GM1 antibodies is differences in the methodology used in their measurement. Technical validation of methodology by identifying serums with high antibody titers is not sufficient. Laboratories must also document the sensitivity and specificity of anti-GM1 antibody testing methods by clinical correlation studies using serums from patients w

Related Conditions

Shared genes

Acute Motor (Axonal) Neuropathy (AMAN)

Antibodies vs Glycolipids & Glycoproteins

Chronic Immune Demyelinating Neuropathies: Variants

Features of motor syndromes: Likely response to therapy

Guillain-Barré-like syndrome with serum IgM binding to GalNAc-GD1a ganglioside

GD1AGM1PATHOLOGY

Lower Motor Neuron Syndrome: Proximal Arm Predominant 1,

Motor neuropathy-Motor neuron syndromes

Multifocal Motor Neuropathy (MMN) & Immune Motor Neuropathies (IMN) 3,14

External Resources

WUSTL Neuromuscular

Washington University Disease Center

Biomedical Literature

NCBI Expert-Authored Reviews

Portal for Rare Diseases

National Organization for Rare Disorders

Data sourced from the Washington University Neuromuscular Disease Center. For clinical use, always refer to primary sources.